- Report
- February 2025
- 138 Pages
Global
From €2000EUR$2,245USD£1,734GBP
- Report
- May 2024
- 420 Pages
Global
From €2863EUR$3,000USD£2,399GBP
- Report
- October 2024
- 184 Pages
Global
From €3383EUR$3,545USD£2,835GBP
€3759EUR$3,939USD£3,150GBP
- Report
- October 2024
- 199 Pages
Global
From €3383EUR$3,545USD£2,835GBP
€3759EUR$3,939USD£3,150GBP
- Report
- May 2024
- 150 Pages
Global
From €5679EUR$5,950USD£4,758GBP
- Report
- March 2025
- 198 Pages
Global
From €5345EUR$5,600USD£4,478GBP
- Report
- March 2025
- 224 Pages
Global
From €4724EUR$4,950USD£3,958GBP
- Report
- March 2025
- 194 Pages
Global
From €4724EUR$4,950USD£3,958GBP
- Report
- March 2025
- 193 Pages
Global
From €5201EUR$5,450USD£4,358GBP
- Report
- March 2025
- 93 Pages
Global
From €5345EUR$5,600USD£4,478GBP
- Report
- March 2025
- 93 Pages
Global
From €5345EUR$5,600USD£4,478GBP
- Report
- March 2025
- 93 Pages
Global
From €5345EUR$5,600USD£4,478GBP
- Report
- February 2025
- 277 Pages
Global
From €5201EUR$5,450USD£4,358GBP
- Report
- March 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- March 2025
- 175 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- February 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- February 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- February 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- May 2024
- 137 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- May 2024
- 130 Pages
Global
From €6203EUR$6,499USD£5,197GBP

Pembrolizumab is a type of oncology drug used to treat certain types of cancer. It is a monoclonal antibody, which works by targeting and blocking a protein called PD-1, which is found on the surface of some cancer cells. This helps the body's immune system to recognize and attack the cancer cells. Pembrolizumab is used to treat a variety of cancers, including melanoma, non-small cell lung cancer, head and neck cancer, Hodgkin lymphoma, and urothelial carcinoma. It is also used in combination with other drugs to treat certain types of advanced or metastatic cancers.
Pembrolizumab is approved by the US Food and Drug Administration (FDA) and is available in the US and other countries. It is typically administered intravenously, and the dosage and duration of treatment depend on the type and stage of cancer being treated.
Some companies in the Pembrolizumab market include Merck & Co., Inc., Bristol-Myers Squibb, AstraZeneca, and Roche. Show Less Read more